Establishing a cell-based screening workflow for determining the efficiency of CYP2C9 metabolism: moving towards the use of breath volatiles in personalised medicine

The use of volatile biomarkers in exhaled breath as predictors to individual drug response would advance the field of personalised medicine by providing direct information on enzyme activity. This would result in enormous benefits, both for patients and for the healthcare sector. Non-invasive breath...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of breath research 2023-10, Vol.17 (4), p.46001
Hauptverfasser: Lochmann, Franziska, Nikolajevic, Aleksandar, Stock, Valentina, Kammerer, Sarah, Fernández-Quintero, Monica L, Loeffler, Johannes R, Liedl, Klaus R, Troppmair, Jakob, Mayhew, Chris A, Ruzsanyi, Veronika
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 4
container_start_page 46001
container_title Journal of breath research
container_volume 17
creator Lochmann, Franziska
Nikolajevic, Aleksandar
Stock, Valentina
Kammerer, Sarah
Fernández-Quintero, Monica L
Loeffler, Johannes R
Liedl, Klaus R
Troppmair, Jakob
Mayhew, Chris A
Ruzsanyi, Veronika
description The use of volatile biomarkers in exhaled breath as predictors to individual drug response would advance the field of personalised medicine by providing direct information on enzyme activity. This would result in enormous benefits, both for patients and for the healthcare sector. Non-invasive breath tests would also gain a high acceptance by patients. Towards this goal, differences in metabolism resulting from extensive polymorphisms in a major group of drug-metabolizing enzymes, the cytochrome P450 (CYP) family, need to be determined and quantified. CYP2C9 is responsible for metabolising many crucial drugs (e.g., diclofenac) and food ingredients (e.g., limonene). In this paper, we provide a proof-of-concept study that illustrates the bioconversion of diclofenac in recombinant HEK293T cells overexpressing CYP2C9 to 4'-hydroxydiclofenac. This approach is a necessary and important first step in the development of breath tests to determine and monitor metabolic processes in the human body. By focusing on the metabolic conversion of diclofenac, we have been able to establish a workflow using a cell-based system for CYP2C9 activity. Furthermore, we illustrate how the bioconversion of diclofenac is limited in the presence of limonene, which is another CYP2C9 metabolising substrate. We show that increasing limonene levels continuously reduce the production of 4'-hydroxydiclofenac. Michaelis-Menten kinetics were performed for the diclofenac 4'-hydroxylation with and without limonene, giving a kinetic constant of the reaction, , of 103 M and 94.1 M, respectively, and a maximum reaction rate, , of 46.8 pmol min 10 cells and 56.0 pmol min 10 cells with and without the inhibitor, respectively, suggesting a non-competitive or mixed inhibition type. The half-maximal inhibitory concentration value (IC ) for the inhibition of the formation of 4'-hydroxydiclofenace by limonene is determined to be 1413 M.
doi_str_mv 10.1088/1752-7163/ace46f
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_2839827280</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2839827280</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-8cac3640b1b2e618d7246543a9e4ded2f9388891a9b7eb982d978d16567385933</originalsourceid><addsrcrecordid>eNp1kc1O3DAUhS1UVGDaPStkqRsWpPgncezu0AjaSkjtAhZdRY593TEk8dROGPFAfU-cGTqVKtUbW9ffOb7XB6FTSj5SIuUlrStW1FTwS22gFO4AHe9Lb_bnqjpCJyk9ECJKItVbdMTrkgjB-DH6fZ1G3XY-rfzwE2tsoOuKViewOJkIMMzlTYiPrgsb7ELEFkaIvd9ejCvA4Jw3HgbzjIPDyx_f2VLhHrJryLb9J9yHpy0bNjratNVMCWa4jaDHFX4KnR59Bwn7Aa8hpjDoLM0t9GCz9wDv0KHTXYL3r_sC3d9c3y2_FLffPn9dXt0WhldqLKTRhucZW9oyEFTampWiKrlWUFqwzCkupVRUq7aGVklmVS0tFZWouawU5wt0vvNdx_BrgjQ2vU_zl-gBwpQaJjlXeeWvW6AP_6APYYq58S2VvWsmSabIjjIxpBTBNevoex2fG0qaOcJmzqiZ82p2EWbJ2avx1Ob594I_mWXgYgf4sP776H_9XgAeh6c9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2839827280</pqid></control><display><type>article</type><title>Establishing a cell-based screening workflow for determining the efficiency of CYP2C9 metabolism: moving towards the use of breath volatiles in personalised medicine</title><source>Institute of Physics Journals</source><creator>Lochmann, Franziska ; Nikolajevic, Aleksandar ; Stock, Valentina ; Kammerer, Sarah ; Fernández-Quintero, Monica L ; Loeffler, Johannes R ; Liedl, Klaus R ; Troppmair, Jakob ; Mayhew, Chris A ; Ruzsanyi, Veronika</creator><creatorcontrib>Lochmann, Franziska ; Nikolajevic, Aleksandar ; Stock, Valentina ; Kammerer, Sarah ; Fernández-Quintero, Monica L ; Loeffler, Johannes R ; Liedl, Klaus R ; Troppmair, Jakob ; Mayhew, Chris A ; Ruzsanyi, Veronika</creatorcontrib><description>The use of volatile biomarkers in exhaled breath as predictors to individual drug response would advance the field of personalised medicine by providing direct information on enzyme activity. This would result in enormous benefits, both for patients and for the healthcare sector. Non-invasive breath tests would also gain a high acceptance by patients. Towards this goal, differences in metabolism resulting from extensive polymorphisms in a major group of drug-metabolizing enzymes, the cytochrome P450 (CYP) family, need to be determined and quantified. CYP2C9 is responsible for metabolising many crucial drugs (e.g., diclofenac) and food ingredients (e.g., limonene). In this paper, we provide a proof-of-concept study that illustrates the bioconversion of diclofenac in recombinant HEK293T cells overexpressing CYP2C9 to 4'-hydroxydiclofenac. This approach is a necessary and important first step in the development of breath tests to determine and monitor metabolic processes in the human body. By focusing on the metabolic conversion of diclofenac, we have been able to establish a workflow using a cell-based system for CYP2C9 activity. Furthermore, we illustrate how the bioconversion of diclofenac is limited in the presence of limonene, which is another CYP2C9 metabolising substrate. We show that increasing limonene levels continuously reduce the production of 4'-hydroxydiclofenac. Michaelis-Menten kinetics were performed for the diclofenac 4'-hydroxylation with and without limonene, giving a kinetic constant of the reaction, , of 103 M and 94.1 M, respectively, and a maximum reaction rate, , of 46.8 pmol min 10 cells and 56.0 pmol min 10 cells with and without the inhibitor, respectively, suggesting a non-competitive or mixed inhibition type. The half-maximal inhibitory concentration value (IC ) for the inhibition of the formation of 4'-hydroxydiclofenace by limonene is determined to be 1413 M.</description><identifier>ISSN: 1752-7155</identifier><identifier>EISSN: 1752-7163</identifier><identifier>DOI: 10.1088/1752-7163/ace46f</identifier><identifier>PMID: 37406623</identifier><identifier>CODEN: JBROBW</identifier><language>eng</language><publisher>England: IOP Publishing</publisher><subject>4ʹ-hydroxydiclofenac ; bioconversion ; Breath tests ; CYP enzymes ; diclofenac ; HEK293T-CYP2C9 cells ; limonene ; Metabolism ; Nonsteroidal anti-inflammatory drugs ; Precision medicine</subject><ispartof>Journal of breath research, 2023-10, Vol.17 (4), p.46001</ispartof><rights>2023 The Author(s). Published by IOP Publishing Ltd</rights><rights>Creative Commons Attribution license.</rights><rights>2023 The Author(s). Published by IOP Publishing Ltd. This work is published under http://creativecommons.org/licenses/by/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c359t-8cac3640b1b2e618d7246543a9e4ded2f9388891a9b7eb982d978d16567385933</cites><orcidid>0009-0009-6223-2329 ; 0000-0002-9284-2242 ; 0000-0002-5014-7241 ; 0000-0001-9631-364X ; 0000-0002-0985-2299 ; 0000-0002-6811-6283</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://iopscience.iop.org/article/10.1088/1752-7163/ace46f/pdf$$EPDF$$P50$$Giop$$Hfree_for_read</linktopdf><link.rule.ids>315,782,786,27933,27934,53855,53902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37406623$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lochmann, Franziska</creatorcontrib><creatorcontrib>Nikolajevic, Aleksandar</creatorcontrib><creatorcontrib>Stock, Valentina</creatorcontrib><creatorcontrib>Kammerer, Sarah</creatorcontrib><creatorcontrib>Fernández-Quintero, Monica L</creatorcontrib><creatorcontrib>Loeffler, Johannes R</creatorcontrib><creatorcontrib>Liedl, Klaus R</creatorcontrib><creatorcontrib>Troppmair, Jakob</creatorcontrib><creatorcontrib>Mayhew, Chris A</creatorcontrib><creatorcontrib>Ruzsanyi, Veronika</creatorcontrib><title>Establishing a cell-based screening workflow for determining the efficiency of CYP2C9 metabolism: moving towards the use of breath volatiles in personalised medicine</title><title>Journal of breath research</title><addtitle>JBR</addtitle><addtitle>J. Breath Res</addtitle><description>The use of volatile biomarkers in exhaled breath as predictors to individual drug response would advance the field of personalised medicine by providing direct information on enzyme activity. This would result in enormous benefits, both for patients and for the healthcare sector. Non-invasive breath tests would also gain a high acceptance by patients. Towards this goal, differences in metabolism resulting from extensive polymorphisms in a major group of drug-metabolizing enzymes, the cytochrome P450 (CYP) family, need to be determined and quantified. CYP2C9 is responsible for metabolising many crucial drugs (e.g., diclofenac) and food ingredients (e.g., limonene). In this paper, we provide a proof-of-concept study that illustrates the bioconversion of diclofenac in recombinant HEK293T cells overexpressing CYP2C9 to 4'-hydroxydiclofenac. This approach is a necessary and important first step in the development of breath tests to determine and monitor metabolic processes in the human body. By focusing on the metabolic conversion of diclofenac, we have been able to establish a workflow using a cell-based system for CYP2C9 activity. Furthermore, we illustrate how the bioconversion of diclofenac is limited in the presence of limonene, which is another CYP2C9 metabolising substrate. We show that increasing limonene levels continuously reduce the production of 4'-hydroxydiclofenac. Michaelis-Menten kinetics were performed for the diclofenac 4'-hydroxylation with and without limonene, giving a kinetic constant of the reaction, , of 103 M and 94.1 M, respectively, and a maximum reaction rate, , of 46.8 pmol min 10 cells and 56.0 pmol min 10 cells with and without the inhibitor, respectively, suggesting a non-competitive or mixed inhibition type. The half-maximal inhibitory concentration value (IC ) for the inhibition of the formation of 4'-hydroxydiclofenace by limonene is determined to be 1413 M.</description><subject>4ʹ-hydroxydiclofenac</subject><subject>bioconversion</subject><subject>Breath tests</subject><subject>CYP enzymes</subject><subject>diclofenac</subject><subject>HEK293T-CYP2C9 cells</subject><subject>limonene</subject><subject>Metabolism</subject><subject>Nonsteroidal anti-inflammatory drugs</subject><subject>Precision medicine</subject><issn>1752-7155</issn><issn>1752-7163</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>O3W</sourceid><recordid>eNp1kc1O3DAUhS1UVGDaPStkqRsWpPgncezu0AjaSkjtAhZdRY593TEk8dROGPFAfU-cGTqVKtUbW9ffOb7XB6FTSj5SIuUlrStW1FTwS22gFO4AHe9Lb_bnqjpCJyk9ECJKItVbdMTrkgjB-DH6fZ1G3XY-rfzwE2tsoOuKViewOJkIMMzlTYiPrgsb7ELEFkaIvd9ejCvA4Jw3HgbzjIPDyx_f2VLhHrJryLb9J9yHpy0bNjratNVMCWa4jaDHFX4KnR59Bwn7Aa8hpjDoLM0t9GCz9wDv0KHTXYL3r_sC3d9c3y2_FLffPn9dXt0WhldqLKTRhucZW9oyEFTampWiKrlWUFqwzCkupVRUq7aGVklmVS0tFZWouawU5wt0vvNdx_BrgjQ2vU_zl-gBwpQaJjlXeeWvW6AP_6APYYq58S2VvWsmSabIjjIxpBTBNevoex2fG0qaOcJmzqiZ82p2EWbJ2avx1Ob594I_mWXgYgf4sP776H_9XgAeh6c9</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Lochmann, Franziska</creator><creator>Nikolajevic, Aleksandar</creator><creator>Stock, Valentina</creator><creator>Kammerer, Sarah</creator><creator>Fernández-Quintero, Monica L</creator><creator>Loeffler, Johannes R</creator><creator>Liedl, Klaus R</creator><creator>Troppmair, Jakob</creator><creator>Mayhew, Chris A</creator><creator>Ruzsanyi, Veronika</creator><general>IOP Publishing</general><scope>O3W</scope><scope>TSCCA</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0009-6223-2329</orcidid><orcidid>https://orcid.org/0000-0002-9284-2242</orcidid><orcidid>https://orcid.org/0000-0002-5014-7241</orcidid><orcidid>https://orcid.org/0000-0001-9631-364X</orcidid><orcidid>https://orcid.org/0000-0002-0985-2299</orcidid><orcidid>https://orcid.org/0000-0002-6811-6283</orcidid></search><sort><creationdate>20231001</creationdate><title>Establishing a cell-based screening workflow for determining the efficiency of CYP2C9 metabolism: moving towards the use of breath volatiles in personalised medicine</title><author>Lochmann, Franziska ; Nikolajevic, Aleksandar ; Stock, Valentina ; Kammerer, Sarah ; Fernández-Quintero, Monica L ; Loeffler, Johannes R ; Liedl, Klaus R ; Troppmair, Jakob ; Mayhew, Chris A ; Ruzsanyi, Veronika</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-8cac3640b1b2e618d7246543a9e4ded2f9388891a9b7eb982d978d16567385933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>4ʹ-hydroxydiclofenac</topic><topic>bioconversion</topic><topic>Breath tests</topic><topic>CYP enzymes</topic><topic>diclofenac</topic><topic>HEK293T-CYP2C9 cells</topic><topic>limonene</topic><topic>Metabolism</topic><topic>Nonsteroidal anti-inflammatory drugs</topic><topic>Precision medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lochmann, Franziska</creatorcontrib><creatorcontrib>Nikolajevic, Aleksandar</creatorcontrib><creatorcontrib>Stock, Valentina</creatorcontrib><creatorcontrib>Kammerer, Sarah</creatorcontrib><creatorcontrib>Fernández-Quintero, Monica L</creatorcontrib><creatorcontrib>Loeffler, Johannes R</creatorcontrib><creatorcontrib>Liedl, Klaus R</creatorcontrib><creatorcontrib>Troppmair, Jakob</creatorcontrib><creatorcontrib>Mayhew, Chris A</creatorcontrib><creatorcontrib>Ruzsanyi, Veronika</creatorcontrib><collection>Institute of Physics Open Access Journal Titles</collection><collection>IOPscience (Open Access)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of breath research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lochmann, Franziska</au><au>Nikolajevic, Aleksandar</au><au>Stock, Valentina</au><au>Kammerer, Sarah</au><au>Fernández-Quintero, Monica L</au><au>Loeffler, Johannes R</au><au>Liedl, Klaus R</au><au>Troppmair, Jakob</au><au>Mayhew, Chris A</au><au>Ruzsanyi, Veronika</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Establishing a cell-based screening workflow for determining the efficiency of CYP2C9 metabolism: moving towards the use of breath volatiles in personalised medicine</atitle><jtitle>Journal of breath research</jtitle><stitle>JBR</stitle><addtitle>J. Breath Res</addtitle><date>2023-10-01</date><risdate>2023</risdate><volume>17</volume><issue>4</issue><spage>46001</spage><pages>46001-</pages><issn>1752-7155</issn><eissn>1752-7163</eissn><coden>JBROBW</coden><abstract>The use of volatile biomarkers in exhaled breath as predictors to individual drug response would advance the field of personalised medicine by providing direct information on enzyme activity. This would result in enormous benefits, both for patients and for the healthcare sector. Non-invasive breath tests would also gain a high acceptance by patients. Towards this goal, differences in metabolism resulting from extensive polymorphisms in a major group of drug-metabolizing enzymes, the cytochrome P450 (CYP) family, need to be determined and quantified. CYP2C9 is responsible for metabolising many crucial drugs (e.g., diclofenac) and food ingredients (e.g., limonene). In this paper, we provide a proof-of-concept study that illustrates the bioconversion of diclofenac in recombinant HEK293T cells overexpressing CYP2C9 to 4'-hydroxydiclofenac. This approach is a necessary and important first step in the development of breath tests to determine and monitor metabolic processes in the human body. By focusing on the metabolic conversion of diclofenac, we have been able to establish a workflow using a cell-based system for CYP2C9 activity. Furthermore, we illustrate how the bioconversion of diclofenac is limited in the presence of limonene, which is another CYP2C9 metabolising substrate. We show that increasing limonene levels continuously reduce the production of 4'-hydroxydiclofenac. Michaelis-Menten kinetics were performed for the diclofenac 4'-hydroxylation with and without limonene, giving a kinetic constant of the reaction, , of 103 M and 94.1 M, respectively, and a maximum reaction rate, , of 46.8 pmol min 10 cells and 56.0 pmol min 10 cells with and without the inhibitor, respectively, suggesting a non-competitive or mixed inhibition type. The half-maximal inhibitory concentration value (IC ) for the inhibition of the formation of 4'-hydroxydiclofenace by limonene is determined to be 1413 M.</abstract><cop>England</cop><pub>IOP Publishing</pub><pmid>37406623</pmid><doi>10.1088/1752-7163/ace46f</doi><tpages>9</tpages><orcidid>https://orcid.org/0009-0009-6223-2329</orcidid><orcidid>https://orcid.org/0000-0002-9284-2242</orcidid><orcidid>https://orcid.org/0000-0002-5014-7241</orcidid><orcidid>https://orcid.org/0000-0001-9631-364X</orcidid><orcidid>https://orcid.org/0000-0002-0985-2299</orcidid><orcidid>https://orcid.org/0000-0002-6811-6283</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1752-7155
ispartof Journal of breath research, 2023-10, Vol.17 (4), p.46001
issn 1752-7155
1752-7163
language eng
recordid cdi_proquest_journals_2839827280
source Institute of Physics Journals
subjects 4ʹ-hydroxydiclofenac
bioconversion
Breath tests
CYP enzymes
diclofenac
HEK293T-CYP2C9 cells
limonene
Metabolism
Nonsteroidal anti-inflammatory drugs
Precision medicine
title Establishing a cell-based screening workflow for determining the efficiency of CYP2C9 metabolism: moving towards the use of breath volatiles in personalised medicine
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T11%3A31%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Establishing%20a%20cell-based%20screening%20workflow%20for%20determining%20the%20efficiency%20of%20CYP2C9%20metabolism:%20moving%20towards%20the%20use%20of%20breath%20volatiles%20in%20personalised%20medicine&rft.jtitle=Journal%20of%20breath%20research&rft.au=Lochmann,%20Franziska&rft.date=2023-10-01&rft.volume=17&rft.issue=4&rft.spage=46001&rft.pages=46001-&rft.issn=1752-7155&rft.eissn=1752-7163&rft.coden=JBROBW&rft_id=info:doi/10.1088/1752-7163/ace46f&rft_dat=%3Cproquest_pubme%3E2839827280%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2839827280&rft_id=info:pmid/37406623&rfr_iscdi=true